Treating Brain Injury with Endogenous Neurogenic Cells

Injection of self-assembling peptides into the brain, which serve as a cellular guide pathway, induces migration of neurons to the damaged area and activates neural regeneration.

Advantage and Core Benefit

  • New treatment concept based on the mechanism of migration of neural stem cells to the injured area and their differentiation into neurons.
  • Expected to be expanded to treatment for brain damage as well as stroke.
  • Neurons could be distributed to any part of the brain in regenerative medicine using neural stem cells

Background and Technology

Neural stem cells are abundant in the subventricular zone (V-SVZ) of the brain and actively produce neurons. It is thought that newly generated neurons migrate within the brain and contribute to neural regeneration after brain injury. The inventors have identified N-Cadherin as a factor required for migration of newly generated neurons, which is expected to be used to treat brain injury and cerebral infarction using endogenous stem cells. However, how to use factors such as N-Cadherin to migrate newborn neurons to the site of injury has been a challenge.
RADA4, a self-assembling peptide consisting of 16 amino acids with RADA repeated four times, is known to self-assemble on fibers when injected into the affected area. The inventors developed RADA4-A16G peptide with improved physical properties (mRADA) and synthesized a peptide that adds N-cadherin to mRADA (Ncad-mRADA) to investigate whether the migration of newborn neurons in the brain can be controlled in the Ncad-mRADA injection group. migration distance from the SVZ was predominantly longer and motor dysfunction after brain injury was improved in the Ncad-mRADA-injected group.


V-SVZ-derived cells matured into neurons in both mRADA- and Ncad-mRADA-injected groups, and the Ncad-mRADA-injected group showed significantly longer migration distance from the V-SVZ (A) and a significantly improved increased slip rate, a factor in left hindlimb motor dysfunction (B)


Patent Pending in Japan
Ohno et. al. Biomaterials (2023)


Dr. Kazunobu Sawamoto (Nagoya City University)


We are looking for companies that are interested in developing neurodegenerative medicines based on our Ncad-mRADA peptide technology. We are also open to collaborations with companies that have cellular drug technologies for neurological diseases; paid MTA for evaluation of mRADA peptides is also available.


Project No: WL-04188


Inquiry Form

    Your name (*required)

    E-mail address (*required)

    Company name

    Message (*required)

    Following submission of your inquiry

    We will contact you shortly to discuss confidentiality, materials transfer, evaluation steps, and licensing opportunities.


    Our support is provided free of charge.
    The information submitted on this form is for business development use only.

    By clicking "Send", you are agreeing to our Privacy Policy.
    If you have questions please reach out to info (at)

    About Tech Manage Corp.
    Copyright © Tech Manage Corp. All Rights Reserved.
    This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.